title: Kinetics of Epstein-Barr Virus (EBV) Neutralizing and Virus-Specific Antibodies after Primary Infection with EBV.
abstract: Prospective studies of antibodies to multiple Epstein-Barr virus (EBV) proteins and EBV neutralizing antibodies in the same individuals before, during, and after primary EBV infection have not been reported. We studied antibody responses to EBV in college students who acquired primary EBV infection during prospective surveillance and correlated the kinetics of antibody response with the severity of disease. Neutralizing antibodies and enzyme-linked immunosorbent assay (ELISA) antibodies to gp350, the major target of neutralizing antibody, reached peak levels at medians of 179 and 333 days after the onset of symptoms of infectious mononucleosis, respectively. No clear correlation was found between the severity of the symptoms of infectious mononucleosis and the peak levels of antibody to individual viral proteins or to neutralizing antibody. In summary, we found that titers of neutralizing antibody and antibodies to multiple EBV proteins increase over many months after primary infection with EBV.
authors.affiliation: Medical Virology Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
authors.forename: Wei
authors.initials: W
authors.lastname: Bu
authors.affiliation: Medimmune, Mountain View, California, USA.
authors.forename: Gregory M
authors.initials: GM
authors.lastname: Hayes
authors.affiliation: Medimmune, Mountain View, California, USA.
authors.forename: Hui
authors.initials: H
authors.lastname: Liu
authors.affiliation: Medimmune, Mountain View, California, USA.
authors.forename: Lorraine
authors.initials: L
authors.lastname: Gemmell
authors.affiliation: Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
authors.forename: David O
authors.initials: DO
authors.lastname: Schmeling
authors.affiliation: Medical Virology Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
authors.forename: Pierce
authors.initials: P
authors.lastname: Radecki
authors.affiliation: Medical Virology Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
authors.forename: Fiona
authors.initials: F
authors.lastname: Aguilar
authors.affiliation: Dental Clinical Research Core, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland, USA.
authors.forename: Peter D
authors.initials: PD
authors.lastname: Burbelo
authors.affiliation: Medimmune, Mountain View, California, USA.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Woo
authors.affiliation: Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, Minnesota, USA Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
authors.forename: Henry H
authors.initials: HH
authors.lastname: Balfour
authors.affiliation: Medical Virology Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA jcohen@niaid.nih.gov.
authors.forename: Jeffrey I
authors.initials: JI
authors.lastname: Cohen
mesh_terms: D056704:Adaptive Immunity; D057134:Antibodies, Neutralizing / Q000097:blood*; D000914:Antibodies, Viral / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay; D004854:Herpesvirus 4, Human / Q000276:immunology*; D006801:Humans; D007244:Infectious Mononucleosis / Q000276:immunology* / Q000473:pathology; D009500:Neutralization Tests; D011446:Prospective Studies; D012720:Severity of Illness Index; D013334:Students; D013997:Time Factors
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral